Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KRAS inhibitor

- PMLiVE

Amgen and TScan Therapeutics partner to identify new Crohn’s disease targets

Inflammatory bowel disease affects nearly one in every 100 people in the US

- PMLiVE

AI model shows promise in detecting lung cancer earlier

Lung cancer accounts for more than 20% of cancer deaths in the UK

- PMLiVE

Long-term study reveals ‘ever-changing’ nature of lung cancer

The researchers hope the findings could help doctors to tailor treatments for individual patients

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

MIT researchers develop AI model to detect future lung cancer risk

Lung cancer is the leading cause of cancer in the US, accounting for 1.7 million deaths globally in 2020

- PMLiVE

AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system

More than 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

AstraZeneca’s severe asthma treatment approved in EU for self-administration

Most healthcare providers, patients and caregivers are able to successfully use the pre-filled pen

- PMLiVE

Amgen and Synaffix sign licensing agreement worth up to $2bn

Amgen will gain access to Synaffix' proprietary antibody-drug conjugates technologies

- PMLiVE

Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022

The acquisition will see Amgen pay $116.50 for each Horizon share in cash

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

Brainomix set to collaborate with NCIMI to assess AI-powered tech in lung cancer care

The partnership will compare automated evaluation versus observations of medical specialists

- PMLiVE

NHS England launches lung cancer awareness drive in country’s cancer hotspots

Only 57% of those surveyed recognised a persistent cough as a symptom of lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links